📰 Rom News
Page 448 - Rom News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rom. Real-time updates on events, politics, business and more.
May 25, 2023
Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor... | May 25, 2023
May 25, 2023
Atrato Onsite Energy PLC - London-based renewable energy investment trust - Net asset value per share as at March 31 grows 1.1% to 93.8 pence from 92.8p at September 30. Looking ahead, notes strong... | May 25, 2023
May 25, 2023
Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023
May 25, 2023
– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline... | May 25, 2023
May 25, 2023
Volkswagen and its Audi unit have agreed to an $85 million settlement in principle over violations of Texas environmental laws stemming from its diesel cheating scandal, Texas Attorney General Ken... | May 25, 2023
May 25, 2023
- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER... | May 25, 2023
May 25, 2023
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022)Median
May 25, 2023
BlackRock Inc. - SBM Offshore N.V. - Schiphol BlackRock Inc. - SBM Offshore N.V. - Schiphol Below you will find information from the register... | May 25, 2023
May 25, 2023
Director Resignation On May 19, 2023, Manish Agarwal, a member of the Board of Directors of HUB Cyber Security Ltd. resigned from the Board and all committees thereof,... | May 25, 2023
May 25, 2023
Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent